Trial Profile
APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms APPRECIATE
- Sponsors Amgen; Celgene Corporation
- 07 Mar 2023 Status changed from recruiting to completed.
- 02 Mar 2023 Results (n=50 from Croatia, Czech Republic and Slovenia) assessing efficacy of apremilast in Severe Psoriasis on the real-world use of apremilast in the Central and Eastern Europe region published in the Advances in Therapy
- 02 Jul 2021 Planned End Date changed from 30 Apr 2021 to 29 Oct 2021.